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Summary CA19-9, a serum marker for pancreatic cancer, gives false-negative results in patients who are
negative for the Lewis blood group phenotype. To determine whether other markers may compensate for this
drawback, serum levels of CA50, Span-l, sialyl SSEA-1 and Dupan-2 were assayed and compared with those
of CA19-9 in 207 normal subjects and in 200 patients with pancreatic carcinoma whose Lewis blood group
phenotypes were confirmed. In normal subjects with the Lewis negative phenotype, the serum levels of CA50
and Span-i, as well as CA19-9, were significantly low, whereas those of sialyl SSEA-1 were independent of the
Lewis blood group phenotype. Serum levels of Dupan-2 were significantly higher in normal subjects with the
Le (a -b-) phenotype as compared with those with Le(a -b+). The sensitivity for pancreatic carcinoma was
81% for CA19-9, 84% for CA50, 82% for Span-i, 51% for sialyl SSEA-1 and 63% for Dupan-2. Among the
39 CA19-9 negative patients, 13 were determined as being Lewis negative by the serum dot-ELISA technique.
Although the positive rates were essentially comparable when each marker was combined with CAl9-9, a
highly elevated serum level of Dupan-2, which strongly suggested the presence of malignancy, was most
frequently encountered in 39 patients who were not diagnosed by CA19-9 assay, especially those with Lewis
negative blood groups. With regard to the three other markers, we found few patients with a highly elevated
serum level in either the Lewis-negative or -positive groups. We conclude that Dupan-2 tended to be elevated
in patients with pancreatic cancer who were negative for the Lewis blood group phenotype.
CA19-9 is generally accepted as being the most reliable serum
marker for diagnosing pancreatic carcinoma (Koprowski et
al., 1979; Del Villano et al., 1983). However, its clinical
application is limited to patients with the corresponding
Lewis antigen phenotype because those individuals with
the Le(a-b-) phenotype cannot synthesise sialyl Lewis A
(CA19-9) (Pour et al., 1988; Hirano et al., 1987). A variety of
other tumour markers, including CA50 (Lindholm et al.,
1983; Holmgren et al., 1984), sialyl SSEA-1 (Fukushi et al.,
1984; Kannagi et al., 1986), Dupan-2 (Metzgar et al., 1982;
Metzgar et al., 1984; Sawabu et al., 1986; Cooper et al.,
1990) and Span-I (Chung et al., 1987; Kiriyama et al., 1990)
have recently been reported as being useful for diagnosing
pancreatic carcinoma. These markers would be expected to
compensate for this diagnostic limitation of CA19-9. How-
ever, there are no publications concerning the incidence of
CA19-9 negative cases of pancreatic cancer as related to the
Lewis blood group system. Few reports have considered
which marker may compensate for this drawback of CA19-9.
The objective of this paper was to clarify this clinical issue.
Accordingly, we studied the influence of the Lewis blood
group system on each of those assays by measuring their
serum levels in normal subjects with various Lewis blood
groups and in patients with pancreatic carcinoma confirmed
to have the Lewis-negative phenotype.
We performed the serum dot-enzyme-linked immunosor-
bent assay (dot-ELISA) for Lewis antigens in 200 patients
with confirmed pancreatic carcinoma to identify those with
a Lewis-negative blood phenotype. A higher prevalence of
Le(a-b-) phenotype has been reported in such conditions
as alcoholic cirrhosis, alcoholic pancreatitis (Stigendal et al.,
1984) and normal pregnancy (Hammer et al., 1981).
Although the exact mechanism for this phenomenon is un-
clear, the amount of antigen absorbed onto the cell mem-
brane from plasma is decreased in those conditions. In a
previous report we showed that, in pancreatic cancer, the
Lewis blood group antigen is frequently lost from the ery-
throcytes leading to false-negative results in haemagglutina-
tion testing, even in the presence of Lewis antigen in serum
or saliva (Hirano et al., 1987). The expression of incompati-
ble Lewis blood-group antigen has also been observed in the
erythrocytes and saliva of other cancer patients (Yazawa et
al., 1988). Many patients with pancreatic cancer showed
Le(a-b-) phenotype by the haemoagglutination technique
and frequently had elevated serum levels of CA19-9. How-
ever, Le(a-b-) patients with elevated CA19-9 levels were
determined to be Lewis positive by the serum dot-ELISA
test. Lewis blood group antigens were rarely observed in the
sera of Le(a-b-) patients with lower serum CA19-9 levels
by this technique. Accordingly, serum dot-ELISA was con-
sidered to be a reliable test for determining the Lewis
negative phenotype of patients with pancreatic cancer who
produce little or no CA19-9.
Materials and methods
Normal subjects and Lewis blood group typing
Citrated blood was collected from 207 apparently healthy
subjects, 97 men and 110 women whose mean age was 47.9 ±
10.4; range 23 to 75 years. The Lewis phenotype of their
erythrocytes was determined by the conventional haemag-
glutination test performed by mixing one drop of red blood
cells suspended in saline with one drop of a solution of
anti-Lea and anti-Leb monoclonal antibodies (Chembiomed,
Edmonton, Canada) respectively.
Identification ofLewis-negative phenotype in patients with
pancreatic carcinoma
Serum dot-ELISA was performed in 200 patients with pan-
creatic carcinoma according to the method of Hawkes et al.
(Hirano et al., 1987; Hawkes et al., 1982). Serum samples
were dropped onto nitrocellulose membrane, blocked with
5% normal goat serum (Dakopats, Glostrup, Denmark), and
reacted with the anti-Lewisa and anti-Lewisb antibodies (9-
fold dilution). The membrane was then exposed to peroxi-
dase-labelled goat anti-mouse IgM (100-fold dilution, Tago,
Burligame, USA) and the colour reaction was subsequently
developed with diaminobenzidine. When a brown colour did
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not develop for either antibody, the patient was considered
to be Lewis antigen-negative.
Assaysfor tumour markers
In addition to CA19-9, we assayed four other tumour mar-
kers in clinical use: CA50, sialyl SSEA-1, Dupan-2 and Span-
1. The following commerical diagnostic kits were used:
CA19-9, radioimmunoassay (RIA) kit (Centcor, Inc. Pennsyl-
vania, USA); CA50, time-resolved fluoroimmunoassay kit
(Pharmacia, Upsala, Sweden); sialyl SSEA-1, RIA kit (Otsu-
ka Assay, Tokusima, Japan); Dupan-2, enzyme-immunoassay
(EIA) kit (Kyowa Medix, Tokyo, Japan); and Span-i, RIA
kit (Dainabbot, Tokyo, Japan). All assays were performed
according to the manufacturer's instructions. A positive
serum level for each marker was defined as being greater
than 37 for CAl9-9, 35 for CA50, 38 for sialyl SSEA-1, 150
for Dupan-2, and 30 U ml-I for Span-i. A highly elevated
level which strongly suggested the presence of malignant
tumour was defined as greater than 150 for each CA50 and
Span-i, 60 for sialyl SSEA-1 and 400 U ml' for Dupan-2
according to previous studies (Kawa et al., 1990; Kobayashi
et al., 1991; Sawabu et al., 1986).
Statistical analysis
Differences among the three Lewis phenotypes in the normal
subjects were evaluated by analysis of variance using the
Bonferroni method (Wallenstein et al., 1980) after the
logarithmic conversion of values. Differences between the
two groups of Lewis phenotype was carried out by the
Chi-square test with Yates' correction. A level of P<0.05
was accepted as statistically significant.
Results
Comparison of tumour marker levelsfor three Lewis
phenotypes in normal subjects (Table I)
In the 207 normal subjects the prevalence of each Lewis
phenotype was as follows: Le(a+b-) 19%, Le(a-b+) 66%
and Le(a-b-) 15%. A significant difference in the serum
levels of CA19-9 was found among the three Lewis pheno-
types. Serum levels of CA19-9 in the Le(a-b-) subjects
were significantly lower (P<0.05) than those of the
Le(a+b-) and Le(a-b+) subjects. Similar results were
obtained with CA50. Serum levels of Span-I were significant-
ly lower (P<0.05) in the Le(a-b-) subjects as compared to
the Le(a +b-) subjects, but there were no significant differ-
ences among the other groups. For sialyl SSEA-1, there were
no significant differences among the three groups of Lewis
phenotypes. Interestingly, the serum levels of Dupan-2 were
significantly higher in the group with the Le(a-b-) pheno-
type as compared with that with the Le(a-b+) phenotype.
Serum tumour marker levels in 200patients with pancreatic
carcinoma andLewisphenotype determined by dot-ELISA
The positive rate for each marker in the patients with pan-
creatic cancer was as follows : 81% for CAl9-9, 84% for
CA50, 82% for Span-i, 51% for sialyl SSEA-l and 64% for
Dupan-2 (Figure 1). A total of 39 patients were not diag-
nosed by the CAl9-9 assay; the number of positive cases for
(%) 50 100
ItI --'-
CAl9-9
l&
M1 _1 _887
CA50
+CA19-9
Span-1
+CA19-9
sialyISSEA-1
85 +CA19-9
Dupan-2
+CA19-9
Figure 1 Summary of positive rate for each marker used alone
or combined with CA19-9 in 200 patients with pancreatic cancer.
each marker among them was similar (Table II) leading to a
similar positive rate when those results were combined with
those of CAl9-9 assay (Figure 1). Of those 39 CA19-9
negative patients, 13 were Lewis-negative by dot-ELISA.
These 13 Lewis-negative cases were positive for each of the
other markers as follows: seven for Dupan-2, five for Span-i,
four for sialyl SSEA-1, and three for CA50 (Table II). In
addition, the serum levels ofDupan-2 were highly elevated in
five of the 13 Lewis negative cases, although only one of the
26 Lewis positive cases showed a marked elevation of this
marker (Tables II, III). Concerning the other markers, mark-
edly elevated serum levels were less frequently observed in
the Lewis negative or positive groups not diagnosed by the
CA19-9 assay (Tables II, III). From these observations, we
conclude that the serum levels of Dupan-2 tended to be
elevated in the Lewis negative patients as compared to other
markers.
Discussion
In this study, the prevalance of each Lewis group in the
normal subjects was similar to that described in our previous
reports (Hirano et al., 1987) and to findings of another study
conducted in normal Japanese controls (Hasekura et al.,
1983; Yazawa et al., 1988). Serum levels of CA19-9 were
significantly lower in normal subjects with the Le(a-b-)
phenotype as compared to those with other Lewis pheno-
types, Le(a+b-) or Le(a-b+). These findings agree with
previous reports (Pour et al., 1988; Hirano et al., 1987) and
support the validity of the methods used in this study.
Although the production of both CA50 and Span-I were
believed to be independent of the Lewis system (Lindholm et
al., 1983; Chung et al., 1987), the serum levels of both
markers in the Le(a -b-) group were significantly lower
than those in Le(a+b-) group. The possible explanation for
this discrepancy was that the monoclonal antibody (MoAb)
Table I Results ofeach marker in 207 normal subjects with reference to Lewis phenotype
Phenotype n (%) CA19-9 CA50 Span-i sialyl SSEA-1 Dupan-2
Le(a+b-) 41 (19%) 15.4±2.1 1 12.8±2.3 1 12.2±1.81 25.5±1.3 11.2±3.5
Le(a-b+) 137 (66%) 8.0±1.81*i * 6.1±2.0]* * 7.2±1.6 * 24.2±1.3 8.9±3.1 Le(a-b-) 31(15%) 3.0+1.7J 1.8±2.5 J 3.3±3.2 i 24.3± 1.2 25.5±3.1]
Le(a+b+) 3 (1%)
Value for each marker represents means± s.d. *P<0.05.
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Table H Results ofeach marker in 39 CAI9-9 negative patients with
pancreatic cancer with reference to Lewis phenotype
Allpatients 200
CA19-9 (-): 39
Lewis phenotype: (-)13 (+)26
CA50(+): 15 (0) 3 (0) 12 (0)
Span-I(+): 13 (3) 5 (2) 8 (1)
sialyl SSEA-1(+): 9 (3) 4 (1) * 5 (2)
Dupan-2(+): 11 (6) 7 (5) 4 (1)
Numbersinparenthesis represent thenumbers ofpatientswithhighly
elevated serum levels. *P<0.05.
Table III Serum levels ofeach marker in 13 Lewis-negative patients
with pancreatic cancer
Patient CA19-9 CA50 Span-i sialyl SSEA-J Dupan-2
1 20 19 16 21 94
2 15 12 7 15 23
3 11 9 47 27 2060
4 16 11 23 23 150
5 32 50 265 34 1510
6 14 2 30 34 1760
7 12 2 73 58 1430
8 0 11 9 29 8
9 30 40 772 114 755
10 0 0 7 25 43
11 0 1 6 54 55
12 0 46 44 46 349
13 5 1 3 25 93
C-50 and the MoAb Span-I also reacted to the CA19-9
(Masson et al., 1985). Because the serum levels of CA50 in
the Le(a- b-) group were also significantly lower than those
in the Le(a-b+) group as seen in the results with CA19-9,
the affinity of the MoAb C50 for CA19-9 was presumed to
be stronger than that of the MoAb Span-1. These findings
agree with Masson's observation that the plasma expression
of CA50 is similar to that of CA19-9 with reference to Lewis
blood cell status (Masson et al., 1990). The serum sialyl
SSEA-1 levels were independent of the Lewis system accord-
ing to its type II structure. In addition, from this result we
confirmed that the MoAb FH-6, the MoAb for sialyl SSEA-
1, had no affinity for CA19-9. The point of greatest interest
arose from the fact that the serum levels of Dupan-2 in the
Le(a-b-) group were significantly higher than those in
Le(a-b+) group. We could not find any similar studies in
the published literature.
The objective of this study was to identify a marker that
might compensate for the drawback of the CA19-9 assay in
diagnosing pancreatic cancer with special reference to the
Lewis blood group system. Overall, we found no difference in
the positive rates when each marker was combined with the
CA19-9 assay. These finding are consistent with our previous
results (Kawa et al., 1990; Kobayashi et al., 1991). However,
among the 39 patients negative for CA19-9 a highly elevated
level which strongly suggested the presence of malignancy
was most frequently seen in Dupan-2 as compared with the
other three markers. Using the dot-ELISA technique, we
confirmed that one-third of the CA19-9 negative patients had
the Lewis-negative phenotype. Concerning the Lewis blood
group system, the prevalence of cases with a highly elevated
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LeC GaIO1-3G1cNAcO1-3Ga1-R - so Ga101-3GIcNAc01-3Gal-R
3
NeuAca2
Le" Ga1O1-3G1cNAcO1-3Ga1-R
4
Fucal
Ga101-3GIcNAcI31-3Gal-R
3 4
IF NeuAca2 uca.l
Leb Ga1O1-3G1cNAcO1-3Ga1-R (CA19-9)
2 4
Fucal Fucal
Figure 2 Proposed pathway for biosynthesis of carbohydrate
antigens.
levels of Dupan-2 was significantly higher in the 13 patients
with the Lewis-negative group as compared to 26 patients
with the Lewis-positive group. These results support the
hypothesis that Dupan-2 may be highly elevated in some
patients with pancreatic cancer who are Lewis-negative as
well as in normal controls. With regard to the three other
markers, we found a few patients with a highly elevated
serum level in either the Lewis-negative or positive groups.
This unfavourable result could be be anticipated from obser-
vations with reference to Lewis blood cell status obtained in
normal subjects. Accordingly we conclude that Dupan-2 was
the most reliable test for diagnosing pancreatic cancer
in Lewis-negative patients who were not diagnosed by the
CAl9-9 assay. Previous reports indicate that CA19-9 and
Dupan-2 were sufficiently independent to complement each
other but could not be substituted for each other (Sawabu et
al., 1986; Cooper et al., 1990).
It is not known why the level of Dupan-2 is higher in
patients with the Le(a-b-) blood cell status. While the
amino acid sequence of the Dupan-2 antigen has been shown
to be a tandem repeat of 20 amino acids in approximately
two-thirds of its protein sequence (Lan et al., 1990), the
structure of the Dupan-2 determinants remains to be eluci-
dated. Previous study has shown that it is a sialylated sugar
chain (Lan et al., 1985). The accelerated synthesis of this
antigen in individuals who are Lewis negative suggests that
its structure may be similar to the sialylated forms of Lewisc
(CA50), which is considered to be a precursor of CA19-9,
and which cannot be converted to it by those who are Lewis
negative (Hansson et al., 1985) (Figure 2). In addition, the
MoAb of Dupan-2 is considered to have little affinity for
sialyl Lewisa (CAl9-9). Immunohistochemical study has dem-
onstrated that Dupan-2 antigens are present in patients who
cannot manufacture CA19-9 (Tempero et al., 1989). Further
study is required to reveal the structure of Dupan-2.
In conclusion, the combined assay of Dupan-2 and CAl9-9
is useful for diagnosing the patient with pancreatic cancer,
because the Dupan-2 assay complements that for CAl9-9
with respect to the Lewis blood group system.
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